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Psoralens are tricyclic furocoumarins with potent pho-
tosensitizing properties in the skin and are now widely 
u sed in the treatment of several dermatologic diseases_ 
In this study the effect of 3 different p soralens 8-me-
thoxypsoralen (8-MOP), 4,5 ',8-trime thylpsoralen (TMP) 
and isopsOl'alen on hepatic microsomal drug-metaboliz-
ing enzymes and cytochrome P-450 has been assessed in 
mice and rats. 8-MOP administered orally to CD-! mice 
daily for 6 days caused 2-3 fold increases in hepatic al'yl 
hYW'ocarbon hydroxylase (AHH), ethylmorphine N-de-
methylase and cytochrome P-450. The absorbance max-
imum of the induced cytochrome was at 450 nm. Aniline 
hydroxylase activity was unchanged. Chronic adminis-
tration of 8-MOP to hairless mice caused significant 
e nhancement of hepatic e thylmorphine N-demethylase 
and cytochrome P-450 but had no effect on AHH; 
whereas chronically administer ed TMP had no signifi-
cant effect on any of these para meters. Isopsoralen a nd 
TMP administe red orally to CD-! mice d a ily for 6 days 
had no effect on any of these liver enzymes or on h epatic 
P-450. 8-MOP administered daily for 6 days to rats 
caused a greater than 4-fold enhancement of AHH and 
greater than 2-fold enhancem ent of ethylmorphine N-
demethylase and cytochrome P-450. These studies indi-
cate that orally administe r ed 8-MOP induces hepatic 
drug-metabolizing enzymes and cytochl"ome P -450 to a 
lesser extent than do the barbituates and suggest that 
this drug could influence the rate of biotransformation 
of concomitantly administered w'ugs in patients un-
d ergoing PUV A therapy. 
The psoralens are naturally occurring furocoumru"in com-
pounds tha t are used clinically in th e treatmen t of selected 
d ermatologic diseases including vitiligo [1], psoriasis [2,3], a nd 
mycosis fungoides [4-6]. D espite t heir widespread u every 
li ttle is Imown concerning the metabolism of these compounds. 
Mandula, Pathak, a nd Dudek demonstrated that one of t he 
psorale ns, trimethylpsorale n (TMP) , is metabolized to 4,8-di-
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methyl, 5'-cru'boxypsoralen in mouse liver and that this m etab-
olite is a lso found in t he mine of huma n subjects [7]. 
Further studies have sh own th at TMP is converted into at 
least 3 separate m etabolites by mouse liver microsomes in vitro 
[8]. This metabolic biotransformation of TMP is dependen t on 
NADPH a nd fulfills the co-factor requirem en ts for a mixed-
function oxidase reaction. An important ch aracteristic of the 
mixed-function oxidase system is t he abili ty of m a ny differen t 
chemicals including drugs to induce its m etabolic activity in 
vru'ious t issues including liver a nd skin [9,10]. No studies have 
rigorously evaluated t he possible induction effects of variou 
psoralens on hepatic and cutaneous drug metabolism a nd cyto-
chrome P-450. Mandula, Path ak, and Dudek did show th at a 
s ingle acute dose of psoralens h ad sligh t induction effects in t he 
liver but no evaluation of t he effect of chronic administration 
of these compounds on t he heme-protein cytoch.rome P-450 was 
performed . 
In the study reported h ere we assessed the effects of system-
ically administered psoralen compounds on t he in vitro hepat.ic 
microsomal m etabo lism of model substrates a nd on cytocluome 
P-450. W e further compared th e induction effects of psoralens 
to those of model inducers such as phenoba rbital and 3-m ethyl-
chola nthl'ene in mice and rats. Finally, t he effect of topically 
a pplied psoralens on cu taneous drug m etabolism was also eval-
uated . 
MATERIALS AND METHODS 
MateriaLs 
4,5',8-trimethylpsoralen (TMP) and 8-methoxypsoralen (8-MOP) 
were gifts from the Paul B. Elder Company (Bryan, Ohio). lsopsoralen 
was isolated from Psoralea corylifolia (leguminosae) and purified and 
chanlcterized by high pressure liquid chromatography, NMR and mass 
spectroscopy in ow' laboratories. All of the psoralens were repeatedly 
recrystallized in hot methanol prior to use in order to maximize puri ty. 
T his was confir med by thin-layer cl1l"omatography, NADPH, 3-methyl-
cholanthrene, and benzo (a) pyrene were obtained from Sigma Chemical 
Company (St. Louis, MO) . All other chemicals were of the highest 
grade commercially available. 
Treatment of Animals 
Male mice (strain CD-I) from the Charles River Breeding Labora-
tories weighing 25-30 gm were treated daily fo r 6 days by oral admin-
istration of 8-MOP, TMP or isopsoralen at a do e of 0.8 mg/ kg/ day. 
Since all of these drugs ru'e highly water insoluble (50 mg/ L) they were 
suspended in 10% gum acacia (USP) and administered p.O. by stomach 
tube. Controls received the vehicle alone. In other experiments the 
effects of orally administered 8-MOP were compared with those of 
typical inducers of drug metabolism such as phenobru'bital (75 mg/ kg/ 
day X 3 in saline) and 3-methylcholanthrene (40 mg/ kg/ day X 3 in corn 
oil) in the CD-l mice. The effects of chronically administered 8-MOP 
(1.2 mg/ kg/ day) S days per week for 6 mo were also evaluated using 
hairless mice (Strain SKH:hr-l obtained from Dr. G Mann, GenetIcs 
Division, Skin and Cancer Hospital, T emple University, Philadelphia, 
Pennsylvania) . 
T he effects of orally administered 8-MOP were also assessed in male 
Sprague-Dawley rats (Holtzm~U1 , Madison Wisconsin). 8-MOP was 
suspended in corn oil by sonication and administered orally at a dose 
of 0.8 mg/kg/day for 6 days. On day 7, the animals were sacrificed. In 
other studies the effect.s of topical application of 8-MOP and 3-MC 011 
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cutaneous AHH was compared in rat skin. The nuchal region of the 
animals was shaved with clippers and treated with topicaUy applied 8-
MOP (50 mg/ kg in acetone) or 3-MC (50 mg/kg) once daily for 3 days 
and the animals sacrified on day 4. 
Preparation of Microsomes 
Twenty-four hours after the last treatment the animals were killed 
by decapitation and washed hepatic microsomes were prepared as 
described previously [12). Whole skin homogena tes were prepared by 
techniques routinely used in these laboratories [13). 
Enzyme Assays 
Cytochrome P -450 concentrations in hepatic microsomes were ana-
lyzed from the dithionite plus carbon monoxide minus dithionite differ -
ence spectrum [14] employing a DW-2a spectrophotometer. Baseline 
correction was obtained using a Midan Microprocessor. The molar 
extinction coeffici ent of 91,000 was used for the absorbance cha nge 
between 450-490 nm to determine the cytochrome P -450 concentra-
tions. Ethylmorpliine N-demethylase activity was determined as de-
scribed by Alvares and Mannering [15]. The formaldehyde formed was 
estimated colorimetrically as described by Nash [16]. Aniline hydrox-
ylase was assayed by measuring the formation ofp-aminophenol by the 
phenol indophenol method ofImai, Ito, and Sato [17]. Aryl hydrocarbon 
hydroxylase activity was determined by a modification of the method 
of Nebert and Gelboin [18] as described previously [12]. The quanti-
tation of phenolic BP metabolites was based on comparison of fluores-
cence to a standard of 3-hydroxybenzo(a)pyrene (3-0HBP). Protein 
was estimated according to Lowry et a l [19]. us ing bovine serum 
albumin as a reference standard. 
Spectral Binding Studies 
Microsomal suspensions containing microsomes equivalent to 100 
mg of liver, wet weight, per ml of 0.1 M K 2HPO.,-KH2PO., buffer, pH 
7.4 , were used. Spectral changes caused by the addit ion of 8-MOP to 
liver microsomes were carried out as described by Schenkman, Rem-
meI', and Estabrook [20]. 
RESULTS 
Comparative Effects of 3 Different Psoralens on Hepatic 
Drug M etabolism and Cytochrome P-450 in Mice 
As shown in Table I, oral administration of isopsoralen and 
8-MOP both caused significant increases in hepatic microsomal 
protein while TMP had no such effect. 8-MOP also caused a 3-
fold increase in AHH activity, a 2-fold increase in ethylmor-
phine N -demethylase activity and a 50% increase in cytoch.rome 
P-450. The absorbance maximum of the 8-MOP-induced he-
patic microsomal heme-protein was at 450 nm (Fig 1). In 
contrast, isopsoralen and TMP evoked no statistically signifi-
cant increases in any of these latter measurements. 
Comparative Effect of 8-MOP ~ith Other Typical Inducers of 
Hepatic Drug-metabolizing E..nzymes 
Inducers of cytochrome P-450 and hepatic drug-metabolizing 
enzymes can be divided into at least 2 broad categories [10]. 
One group, of which phenobarbital is a typical example, en-
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hances the biotransformation of a large number of substrates 
and increases a microsomal heme-protein with an absorbance 
maximum at 450 nm. The second group, of which 3-methylcho-
lanthrene is a typical example, enhances the metabolism of a 
much smaller number of substrates and induces a microsomal 
heme-protein known as P-448 or P,-450 [19] that is spectrally 
and catalytically distinct from P-450. The enzyme induction 
effect of 8-MOP was compared to that of phenobarbital and 3-
methylcholanthrene in an effort to identify the category of 
inducer to which it belongs. 
As shown in Table I, both 8-MOP and phenobarbital caused 
significant increases in hepatic microsomal protein content and 
in AHH activity while 3-MC had no such effect. Both pheno-
barbital and 3-MC significantly enhanced aniline hydroxylase 
activity while 8-MOP did not. Phenobarbital and 8-MOP each 
caused significant increases in ethylmorphine N-demethylase 
activity and in the levels of cytochrome P-450. These data 
indicate that 8-MOP is a phenobarbital type of inducer in CD-
1 mouse liver. In further studies the spectral characteristics of 
the cytochrome P-450 induced by 8-MOP were compared with 
those evoked by phenobarbital and 3-MC. The CO-difference 
spectra of liver microsomes from control mice and from mice 
treated with 8-MOP, phenobarbital and 3-MC are shown in Fig 
1. As would be expected liver microsomes from controls and 
phenobarbital-treated animals showed an absorption maximum 
at 450 nm, whereas microsomes from 3-MC treated animals 
showed an absorption maximum at 448 nm. Liver microsomes 
isolated from 8-MOP treated mice demonstrated a peak ab-
sorbance at 450 nm. These data indicate that 8-MOP is a 
phenobarbital type of heme-protein inducer though its potency 
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FIG 1. Comparative CO-difference spectra 0[' rat liver microsomes 
in anima ls trea ted with various inducers of hepatic drug-metabolizing 
enzyme activity. 
TABLE I. Comparative effects of orally administered isopsoralen, trim.ethyipsoralen and 8-methoxypsoralen (0.8 m.g/hg/day x 6) to CD· ] 
m.ice on hepatic cy(;ochrome P-450 levels and drug m.etaboliz ing enzyrne activities 
Microsomal protein 
Aryl hydrocarbon hy- Aniline hydroxylase Trea tment droxylase (mg/gram wet weight) pmol 3-01) BP/min/ (nmol PAP/ min/ mg pro· 
mg protein tein) 
Contro l 15.8 ± 0.5" 122 ± 7 1.83 ± 0.03 
Isopsoralen 19.6 ± 0.4 117 ± 10 1.68 ± 0.09 
Trimethylpsor- 16.0 ± 0.2 150 ± ]0 1.83 ± 0.08 
a len 
8-Methoxypso- 18.0 ± 0.5" 345 ± 4" 2.03 ± 0.15 
ralen 
Phenobarbital 23.2 ± 1.6" 245 ± 16/' 2.77 ± 0.18" 
3-Methylcho- 18.4 ± 1.3 1140 ± 42 2.32 ± 0.13" 
lanthrene 
" Data represent mean ± SE of at least 3 separa te sets of pooled livers from 3 mice. 
" S ignificantly different fTom controls (p < 0.05) . 
Ethylmorphine N-demeth-
yl!lse Cytochrome P-450 
nnwl HCHO/ ll1in/ lllg pro- (nll1ole/ll1g I" 'olein) 
tein) 
8.43 ± 1.00 1.10 ± 0.04 
7.03 ± 1.33 1.04 ± 0.05 
7.l3 ± 0.04 U6 ± 0.02 
16.60 ± 1.17" 1.58 ± 0.06" 
27.22 ± 1.33" 2.48 ± 0.06/' 
8. 18 ± 1.17 1.26 ± 0.03 
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as an inducer appears to be considerably less than that of the 
barbiturate. 
E ffects of Chronic Adm in istration of 8-MOP and TMP on 
H epatic Drug Metabo lism in Hairless Mice 
logic therapy because of their ability to function as photosen-
sitizers and as inhibitors of DNA synthesis. In the presence of 
longwave ultraviolet radiation (UV -A or 320-400 nm) the pho-
toactivated psoralens form covalent bonds with pyrimidine 
As shown in T able II, oral administration of 8-MOP for 6 m o 
evoked a significant increase in ethylmorphine N-demethylase 
activity and in cytochr ome P-450 levels but had not effect on 
AHH activity. Chronically administered T M P caused no de-
tectable changes in any of these measurements. 
E ffect of 8-MOP on Hepatic Drug Metabolism in Sprague-
Dawley Rats 
T hese studies were carried out in Sprague-Dawley rats to 
further characterize the enzyme induction effects of 8-MOP in 
another widely studied animal species. As shown in Table III, 
8-MOP caused significant increases in liver microsomal AHH 
a nd ethylmorphine N-demethylase activities and in cytociu'ome 
P-450 levels bu t had no effect on microsomal protein content, 
or on a niline hydroxylase activity. CO-di fference spectra of 
hepatic microsomes prepared fTom these animals also con-
firmed that 8-MOP induced a heme-protein with an absorbance 
maximum at 450 nm. In addition, t he ethyl isocyanide difference 
spectra of microsomes from control and 8-M OP treated rats 
showed 455:430 peak ratios of 0.64 and 0.66 respectively (Table 
III). T his is also consistent with a phenobarbital type of induc-
tion response. 
Binding Spectrum, of 8-MOP to Control Liver Microsomes 
Compounds interact with hepatic microsomal suspensions to 
give a Type I difference spectrum, characterized by a peak at 
about 385 nm and a trough at about 420 nm, or a Type II 
diffe rence spectrum, characterized by a peak at about 430 nm 
and a trough at about 390 nm. As shown in F ig 2, addition of 8-
MOP resul ted in a Type I difference spectrum which is identical 
to that of hexabaJ·bital. T his finding indicates that 8-MOP 
interacts with liver microsomes sim ilal' to other Type I com-
pounds. 
E ffect of Topical Application of 8-MOP and 3-MC on AHH, 
a Drug-metaboliz in.g E nzyme in Rat Sllin 
In these studies an effor t was made to determine whether 
topically applied 8-MOP had any induction effect on cutaneous 
drug metabolism . The activity of the car cinogen-metabolizing 
enzyme, AHH, was assessed as shown in Table IV. 3-Me caused 
a 20-fo ld enhancement of the skin enzyme whereas 8-MOP had 
no ind uction effect whatsoever. T his is of interest since it is 
consistent with our data in liver indicating that 8-MOP is an 
inducer of the barbiturate type which characteristically has 
little or no induction effect upon drug metabolizing enzyme 
activity in the skin. 
DISCUSSION 
Psora lens (B-methoxypsoralen and psoralen) have been used 
since antiqui ty in the treatment of the amelanotic skin disease 
known as vitiligo [22] and more recently 8-M OP has been used 
in the treatment of psoriasis [3], mycosis fungoides [4J and 
seve ral other skin disorders. T he linearly anllulated photoreac-
tive psoralens are furocoumarin compounds useful in dermato-
TABLE III. Effect of orally administered 8-methoxypsoralen to 
Sprague-Dawley rats on. hepa.tic cytochrome P-450 levels and drug 
m.etaboliz ing enzym e activities 
Measurement Controls 8-Methoxypsol'll-len 
Liver weigh t 5.66 ± 0.39" 5.47 ± 0.26 
(grams) 
M icrosomal protein 22.5 ± 0.5 23.8 ± 0.6 
(mg/gram wet 
weigh t) 
AHH 83.5 ± 6.2 334.5 ± 19.5" 
(pmol 3-0HBP; 
min/ mg protein) 
Aniline hydroxylase 0.80 ± 0.05 0.73 ± 0.03 
(nmol PAP/ mini 
mg protein) 
Ethylmorphine N-de- 6.53 ± 0.25 15.22 ± 0.05" 
methylase 
(nmol HCHO/ min/ 
mg protein) 
Cytoch rome P-450 0.74 ± 0.02 1.52 ± 0.09" 
(nmol/mg protein) 
Ethyl isocyanide dif- 0.64 ± 0.01 0.66 ± 0.04 
Ference spectra 
(Ratio of 455:430 
Peaks) 
" Data represent mean ± SE of 5 rats. 
"Significantly different from control (p < 0.05). 
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FIG 2. Binding spectrum of 8-MOP to control rat liver microsomes. 
TABLE IV. Comparative effect of topical application of 3-
l1I.ethylcholanthrene and 8- l1I.ethoxypsora.len on cutan eolls ary l 
hydrocarbon hydroxylase in. Il eona.tal rat s 
T reatment. 
Control 
3-Methylcholantlu'ene 
8-Methoxypsoralen 
Aryl hydrocarbon hydroxyla~e 
(pmol 3-0HBP/ min/ mg protem) 
0.58 ± 0.06" 
10.36 ± 0.17/' 
0.60 ± 0.08 
" Data represent mean ± SE of 5 experiments. 
"Significantly different fTom control (p < 0.05). 
TAULE II. Effect of chronic oral administration of 8-methoxypsoralen and lrimethyipsora.len (1.2 mg/ lig/ day-5 days/ lUeeh for 6 mo) to 
hairless m.ice on hepatic cytochrome P-450 levels and drug-m etaboliz ing enzyme activities 
T reat.ment Microsomal protein 
mg/ g wet tissue weight 
Aryl hyd rocarbon hyd roxylase Ethylmorphine N-demethylase 
pll\o l 3-0I-lBP/ mill / lI1g protein 1111101 HCHO/ l1 lin/ rng prol ein 
Control 12.6 ± 1.4" 124 ± J3 
8-Methoxypsoralen J.3.4 ± 0.9 122 ± 14 
T rimcthylpsoralen 12.2 ± 1.0 117 ± 15 
" Data represent mean ± SE of at least 3 'eparate sets of pooled livers from 2 mice. 
b S ignificantly different from cont rol (p < 0.05) . 
13.2 ± 0.8 
2.22 ± 1.5" 
12.8 ± 0.7 
Cytochrome P-450 
nrnol/rng protem 
0.78 ± 0.03 
1.23 ± 0.14" 
0.0 ± 0.05 
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bases in DNA [23,24). These light-activated cycloaddition prod-
ucts are formed between the 3,4, or 4' ,5', position of the psoralen 
molecule and the 5,6 position of pyrimidine bases [24,26). Cross-
links between opposite strands of DNA are subsequently 
formed which in turn may account for the known ability of 
psoralens to inhibit DNA synthesis and replication. Previous 
studies have also shown that topically applied or orally admin-
istered psoralens in combination with UV -A can form cycload-
dition products and crosslinks with DNA of skin cells in exper-
imental animals and in humans receiving photo chemotherapy 
with psoralens [27). 
Despite the increasing clinical use of the psoralens in treating 
a variety of dermatologic diseases, relatively little is known 
concerning the absorption, distribution and metabolism of these 
compounds either in experimental animals or in humans. Orally 
administered psoralens are almost totally absorbed in the gas-
trointestinal tract and less than 5% can be detected in the feces 
[29,30]. Within 12 hr more than 90% of an orally administered 
dose of 8-methoxypsoralen can be found in the urine primarily 
as glucuronides or as hydroxylated moieties. Maximum blood 
levels of these drugs occur 2-3 hours following oral administra-
tion after which they appear to be rapidly excreted in the urine. 
Little is known concerning the metabolism of psoralens by 
the liver or other tissues. Mandula, Pathak, and Dudek have 
shown that TMP is apparently metabolized in part to 4,8-
dimethyl, 5' -carboxy-psoralen (DMeCP), a nonphotosensitizing 
metabolite which can be detected in the urine of mice and of 
humans to whom TMP is administered orally [7). Recent 
studies have shown that microsomes obtained from untJ'eated 
CD-1 mice are capable of metabolizing TMP to DMeCP as well 
as to selected other metabolites in vitro [8). These studies also 
showed that this reaction required NADPH and oxygen for 
optimal catalytic activity. Thus TMP appears to be metabolized 
at least in part by the hepatic microsomal cytochrome P-450-
dependent mixed-function oxidase system. 
8-MOP, on the other hand, does not appear to be appreciably 
metabolized ~n mice or in humans although at least 4 metabo-
lites are observed in the urine of mice and of human subjects 
receiving oral 8-MOP [31). Careful analysis of urine from ani-
mals and humans receiving 8-MOP showed that only a small 
percentage «5%) is excreted as the unmetabolized parent 
compound. Kolis et al studied the metabolism of HC-8-MOP in 
dogs [32). They isolated several metabolites from the urine 
including 7 -hydroxy-8-methoxy-2-oxo-2-H-1 benzopyran-6-
acetic acid, a,7-dihydroxy-8-methoxy-2-oxo-2H-1-benzopyran-6 
acetic acid and (Z)-3-(6-hydroxy-7-methoxybenzofuran-5-yl)-2 
propenoic acid. 
We attempted all manner of variation of standard methods 
of in vitro incubation of 8-MOP with micro somes from un-
treated CD-l mice and coulCl find no evidence of metabolite 
formation. In other studies we have attempted without success 
to d~monstrat~ in vitro metabolism of 8-MOP by microsomal 
fractlOns obtamed from rats and mice (either untreated or 
treate~ with p~enobarbital, 3-methylcholanthrene, or the pol-
ychlormated blphenyls (PCBs) , unpublished observations). A 
major limiting factor in these in vitro assay systems is the very 
poor water solubility (approximately 50 mg/L) of the 8-MOP 
which may inhibit its ability to penetrate the microsomal mem-
branes. 
Data presented in this paper indicate that treatment of mice 
and rats with psoralens can cause enhancement of hepatic 
microsomal drug metabolism and the heme-protein cytochrome 
P-450. Of the 3 psoralens studied 8-MOP was the only one 
which had consistently significant effects of drug-metabolizing 
enzymes and cytochrome P-450. Thus, short-term (daily for 6 
days) 8-MOP administration caused significant increases in 
microsomal protein concentration, AHH and ethylmorphine N-
demethylase activities and cytochrome P-450 concentrations in 
mouse liver. Chronic administration (5x weekly for 6 mol of 8-
MOP also caused significant increases in ethylmorphine N-
demethylase and cytochrome P-450. Short-term administration 
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of 8-MOP to Sprague-DaWley rats caused significant increases 
in hepatic microsomal AHH, ethylmorphine N-demethylase 
and cytochrome P-450 while TMP had no effect upon any of 
these measurements. 
Spectral studies of the 8-MOP-induced heme-protein indi-
cated that the absorbance maximum was at 450 nm, similar to 
that of control or phenobarbital-treated animals. Ethyl isocya-
nide difference spectra also showed that microsomes prepared 
from 8-MOP treated animals demonstrated a 455:430 peak ratio 
similar to that of control or phenobarbital-treated animals. The 
addition of 8-MOP to liver microsomes resulted in a Type I 
difference spectrum. These findings, in aggregate, suggest that 
8-MOP may be a substrate for liver microsomes although we 
were unable to verify this possibility in the studies described 
here. 
Skin application of 8-MOP to neonatal rats had no effect 
upon cutaneous AHH activity an enzyme which in this tissue 
normally increases in activity following treatment with poly-
cyclic aromatic hydrocarbon carcinogens such as 3-MC. Thus, 
8-MOP does not appear to influence this microsomal enzyme 
system in the skin. 
In summary, our studies indicate that 8-MOP is a moderately 
potent inducer of hepatic microsomal drug-metabolizing en-
zymes and cytochrome P-450 and that the induction response 
to this drug is analagous to that which occurs in animals treated 
with barbiturates. 
Our data indicate that administration of 8-MOP to patients 
undergoing PUV A therapy may alter rates of hepatic metabo-
lism of concomitantly administered drugs. While the enzyme 
induction effect of 8-MOP is qualitatively similar to that evoked 
by the barbiturates, it is quantitatively much less effective in 
this regard. These findings suggest that the interaction of 
psoralens with the hepatic metabolism of other drugs is likely 
to pose a less serious problem than that which has been attrib-
uted to the barbiturates. 
The authors are grateful to Mrs. Carole Neely and Mrs. Sandra 
Palmer who typed the manuscript. 
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Reduction of the Fraction of Circulating Helper-Inducer T Cells 
Identified by Monoclonal Antibodies in Psoriatic Patien~s Treated with 
Long-term Psoralen/Ultraviolet-A Radiation (PUV A) 
RICHARD A. MOSCICIU, M.D., WARWICK L. MORISON, M.D., JOHN A. PARRISH, M.D., KURT J. BLOCH, M.D. , 
AND ROBERT B. COLVIN, M.D. 
The Inununopathology Unit of the Department of Pathology, th.e Photom.edicine Unit of the Departm.enl of Dermatology, and the Clinical 
Immun.ology and Allergy Units of the M edical Services, Massachuselts General Hospital, Boslon, Massaclwsetts, U.S.A. 
illtraviolet radiation has been found to alter the dis-
tribution and function of human lymphocytes. To deter-
mine whether photochemotherapy (PUV A) alters circu-
lating levels of T cell subset marker-bearing lympho-
cytes, cells from 9 patients with psoriasis undergoing 
PUV A therapy for several years (mean 4.6 ± 1.4 yr), 17 
patients with active untreated psoriasis, and 20 healthy 
volunteers were reacted with monoclonal antibodies to 
T cell surface markers, including OKT3 (all peripheral 
blood T cells), OKT4 (helper/inducer T cells), OKT6 
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Abbreviations: . 
Con A: concanavalin A 
pSS: phosphate-buffered saline 
PRA: phytohemagglu tinin 
'(common thymocytes), and ORT8 (suppressor/cytotoxic 
T cells), and analyzed by flow cytometry. There were no 
differences in the distribution of T cell subsets between 
healthy volunteers and patients with active psoriasis. In 
contrast, the percentages of lymphocytes reacting with 
OKT3 and OKT4 were lo~er (by 16% and 12% percent 
.respectively, p < 0.0025) in the PUV A-treated patients 
compared to healthy volunteers or patients with active 
psoriasis that had not received PUV A therapy. There 
was no difference in the percentage of OKTS and OKT6 
bearing cells. Squamous cell carcinoma of the skin sub-
sequently developed in 2 of 3 PUV A-treated patients 
with 'the lowest percentages of T4-bearing cells. These 
findings indicate that long-term PUV A therapy is asso-
ciated with a reduction in circulating helper/inqucer T 
cells. This reduction may have a . role in tile altered 
immune function reported in PUV A-treated patien~s. 
Ultraviolet radiation can alter the distribution and function 
of lymphocytes both in animal$' and humans [1-6]. Oral psora-
len and subsequent exposUl'e tb ul.traviolet-A radiation (PUYA) 
